A phase II open label study of CB7630 (abiraterone acetate) in patients with advanced prostate cancer who have failed androgen deprivation and docetaxel-based chemotherapy.
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Abiraterone acetate (Primary) ; Corticosteroids
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Cougar Biotechnology
- 08 Aug 2012 Actual end date (1 Aug 2011) added as reported by ClinicalTrials.gov.
- 16 Feb 2011 Planned end date changed from 1 Dec 2007 to 1 Jun 2011 as reported by ClinicalTrials.gov.
- 16 Feb 2011 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.